AirWare Labs Files Patent Application for Revolutionary Oxygen Cannula Delivery System

AirWare Labs Files Patent Application for Revolutionary Oxygen Cannula Delivery 
New Nasal Cannula System Will Resolve Common Patient Complaints and
Improve the Effectiveness of Oxygen Therapy; Global Market Predicted
to Reach $13.5 Billion by 2015 
SCOTTSDALE, AZ -- (Marketwired) -- 07/09/14 --  AirWare Labs Corp.
(OTCQB: AIRW) today announced the filing of a new patent application
for a revolutionary oxygen cannula delivery system, expected to
launch later this year. The system will feature a proprietary cannula
design, fitted with disposable nasal dilators that diffuse the stream
of oxygen as it enters the nasal passage and prevent the nasal
dryness, irritation and discomfort commonly reported by cannula
users. The nasal dilators also work to open the nasal passage and
increase airflow by up to 60%, enhancing the overall effectiveness of
oxygen therapy. 
Commonly prescribed for patients with chronic shortness of breath,
sleep-related breathing disorders and chronic obstructive pulmonary
disease (COPD), oxygen therapy has been widely provided through a
nasal cannula system since the 1940s. Largely unchanged since its
inception nearly 75 years ago, the traditional nasal cannula causes a
myriad of patient complaints, including nasal passage dryness,
irritation and failure to stay in place while the patient is asleep.
In addition, the potential for contamination and infection from
improperly cleaned cannulas is a pervading problem. 
According to the National Heart, Lung and Blood Institute, over 12
million people in the U.S. have been diagnosed with COPD and an
additional 12 million are likely to have it without realizing it. A
recent international survey found that worldwide prevalence ranged
from 7%-9% (up to 640 million people). With home oxygen patients
averaging two or three cannulas a month, an estimated 800 million
cannulas are used annually for oxygen therapy alone. 
"With millions of people worldwide using nasal cannulas for oxygen
therapy, it's surprising that the same issues with dryness and
irritation have persisted since the 1940s," said Jeffrey Rassas, CEO
of AirWare Labs. "We're very excited to bring to market a highly
effective solution for these common complaints that will also
significantly lower the risk of infection or contamination. The
diffused air stream will greatly reduce dryness, and the inserts are
designed to hold the cannula in place while the oxygen recipient is
The global market for respiratory care devices, including oxygen
cannulas, is expected to reach $13.5 billion by 2015, according to
market research and consulting company MarketsandMarkets. 
About AirWare Labs Corporation: 
AirWare Labs Corp., publicly traded as (OTCQB: AIRW), provides
patented and innovative technology solutions for consumer products
that promote better health through breathing and enhanced wellbeing.
AirWare Labs' products are marketed under the brand name of AIR(R).
AIR(R) products utilize an FDA approved medical grade material,
molded as an intranasal Air Breathe dilator, to act as the delivery
system. This AIR(R) microstructure enhances normal nasal airflow with
every breath -- clinically proven to deliver up to 40% more oxygen.  
Some AIR(R) products are infused with essential oils with unique
healing properties including antibacterial and therapeutic defense
against airborne allergens, viruses and bacteria. AIR(R) Allergy and
Travel products provide additional defense in the form of an
integrated filter media from 3M to remove microscopic particles that
carry viruses, allergens and bacteria. Other AIR(R) specialty
products help provide performance enhancements and relief from
congestion, insomnia, headaches, nausea, and snoring. For more
product information, please visit: or
company information visit: 
Forward-Looking Statement: The statements in this press release
regarding any implied or perceived benefits from the release by
AirWare Labs Corp. of its products are forward-looking statements.
Such statements involve risks and uncertainties, including, but not
limited to, risks and effects of legal and administrative proceedings
and governmental regulation, especially in a foreign country, future
financial and operational results, competition, general economic
conditions, and the ability to manage and continue growth.  
Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual outcomes may
vary materially from those indicated. Important factors that could
cause actual results to differ materially from the forward-looking
statements we make in this news release include the introduction of
new technology, market conditions and those set forth in reports or
documents we file from time to time with the SEC. We undertake no
obligation to revise or update such statements to reflect current
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events. 
Media Contact: 
Jennifer Breitegan 
Investor Relations:
Keith Pinder
Acorn Management
Press spacebar to pause and continue. Press esc to stop.